References
- World Health Organization. Global Cancer Observatory (GCO). [cited 2019 Aug 16]. Available from http://gco.iarc.fr
- Balogh J, Victor D 3rd, Asham EH, et al. Hepatocellular carcinoma: a review. J Hepatocell Carcinoma. 2016;3:41–53.
- National Comprehensive Cancer Network. NCCN Guidelines Version 3.2019: Hepatobiliary cancers, Accessed 2019 Aug 16. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hepatobiliary.pdf.
- Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–390.
- Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391(10126):1163–1173.
- Vilgrain V, Pereira H, Assenat E, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18(12):1624–1636.
- Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36(19):1913–1921.
- Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379(1):54–63.
- Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716–723.
- Schwarz GE. Estimating the dimension of a model. Ann Statist. 1978;6(2):461–464.
- National Institute for Health and Care Excellence. Assessing resource impact process manual: technology appraisals and highly specialised technologies. London, UK. 2017. [cited 2020 Jan 23]. Available from https://www.nice.org.uk/Media/Default/About/what-we-do/Into-practice/assessing-resource-impact-process-manual-ta-hst.pdf
- Ghabri S, Autin E, Poullié AI, et al. The French National Authority for Health (HAS) guidelines for conducting Budget Impact Analyses (BIA). Pharmacoeconomics. 2018;36(4):407–417.
- Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123–152.
- National Institute for Health and Care Excellence. Lenvatinib for advanced, unresectable, untreated hepatocellular carcinoma [ID1089] appraisal consultation document. [cited 2019 Sep 5]. Available from https://www.nice.org.uk/guidance/indevelopment/gid-ta10150/documents.
- Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389(10064):56–66.
- Sancho L, Rodriguez-Fraile M, Bilbao JI, et al. Is a technetium-99m macroaggregated albumin scan essential in the workup for selective internal radiation therapy with yttrium-90? An analysis of 532 patients. J Vasc Interv Radiol. 2017;28(11):1536–1542.
- Sangro B, Carpanese L, Cianni R, et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011;54(3):868–878.
- Ferlay J, Ervik M, Lam F, et al. International Agency for Research on Cancer. France. 2018. [cited 2019 Sep 5]. Available from https://gco.iarc.fr/today
- Institut national de la statistique et des études économiques. Démographie – Population au début du mois – France (inclus Mayotte à partir de 2014). Paris, France. 2019. [cited 2019 Sep 5]. Available from https://www.insee.fr/en/statistiques/serie/001641607
- Istituto Nazionale di Statistica. Bilancio demografico mensile: Periodo gennaio-marzo 2019. Rome, Italy. 2019. [cited 2019 Sep 5]. Available from http://demo.istat.it/pop2019/index_e.html
- Instituto Nacional de Estadística. Demografía y población: Población residente en España. Madrid, Spain. 2019. [cited 2019 Sep 5]. Available from http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_C&cid=1254736176951&menu=ultiDatos&idp=1254735572981
- Office for National Statistics. Population estimates time series dataset (pop): England population mid-year estimate. [cited 2019 Sep 5]. Available from https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/timeseries/enpop/pop
- Altekruse SF, Devesa SS, Dickie LA, et al. Histological classification of liver and intrahepatic bile duct cancers in SEER registries. J Registry Manag. 2011;38(4):201–205.
- Costentin CE, Mourad A, Lahmek P, et al. Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study: delayed diagnosis of alcohol-related HCC. Cancer. 2018;124(9):1964–1972.
- Giannini EG, Farinati F, Ciccarese F, et al. Prognosis of untreated hepatocellular carcinoma. Hepatology. 2015;61(1):184–190.
- Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155–2166.
- Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in France and in the United States. Hepatology. 2017;65(4):1237–1248.
- Mickisch G, Gore M, Escudier B, et al. Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib. Br J Cancer. 2010;102(1):80–86.
- Rognoni C, Ciani O, Sommariva S, et al. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer. 2018;18(1):715.
- Rognoni C, Ciani O, Sommariva S, et al. Cost-effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. J Comp Eff Res. 2018;7(3):209–221.
- Vouk K, Benter U, Amonkar MM, Marocco A, et al. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 2016;19(9):900–912.
- Wehler E, Zhao Z, Pinar Bilir S, et al. Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ. 2017;18(1):49–58.
- Gazzetta Ufficiale della Repubblica Italiana. Rinegoziazione del medicinale per uso umano «Nexavar» ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993, n. 537. (Determina n. DG 411/2018). [cited 2019 Sep 5]. Available from https://www.gazzettaufficiale.it/eli/id/2018/04/05/18A02265/sgLast
- Gazzetta Ufficiale della Repubblica Italiana. Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano «Lenvima». (Determina n. 718/2016). [cited 2019 Sep 5]. Available from https://www.gazzettaufficiale.it/eli/gu/2016/06/10/134/sg/pdf
- Gazzetta Ufficiale della Repubblica Italiana. Regime di rimborsabilita’ e prezzo, a seguito di nuove indicazioni terapeutiche, del medicinale per uso umano «Stivarga». (Determina n. 1399/2018). [cited 2019 Sep 5]. Available from https://www.gazzettaufficiale.it/eli/id/2018/09/25/18A06064/SG.
- Osakidetza. Tarifas para Facturación de Servicios Sanitarios y Docentes de Osakidetza para el Año 2018. [cited 2019 Oct 10]. Available from https://www.osakidetza.euskadi.eus/contenidos/informacion/libro_tarifas/es_libro/adjuntos/TARIFA_2018_CAS.pdf
- Pericay C, Frías C, Abad A, et al. Análisis coste-efectividad de aflibercept en combinación con FOLFIRI en el tratamiento de pacientes con cancer colorrectal metastásico. Farm Hosp. 2014;38(4):317–327.
- NICE British National Formulary. [cited 2019 Aug 16]. Available at http://bnf.nice.org.uk/
- Curtis LA, Burns A. Unit costs of health and social care 2018. Project report. Canterbury, UK: University of Kent; 2018.
- National Health Service England Improvement. Reference costs. [cited 2019 Aug 16]. Available from https://improvement.nhs.uk/resources/reference-costs/
- Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991;20(8):2609–2631.
- Branson M, Whitehead J. Estimating a treatment effect in survival studies in which patients switch treatment. Statist Med. 2002; 21(17):2449–2463.
- Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56(3):779–788.
- Vilgrain V, Abdel-Rehim M, Sibert A, et al. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Trials. 2014;15(1):474.
- Cheng A-L, Qin S, Ikeda M, et al. IMbrave150: efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 2019;30(S9):ix186–ix187.
- Food and Drug Administration. Cabometyx (cabozantinib) supplement approval. Silver Spring, MD, USA: Food and Drug Administration; 2019. [cited 2020 Jan 23]. Available from https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2019/208692Orig1s003ltr.pdf
- European Medicines Agency. Cabometyx-H-C-004163-II-0005: EPAR – Assessment report – variation. Amsterdam, Netherlands; 2018. [cited 2020 Jan 23]. Available from https://www.ema.europa.eu/en/documents/variation-report/cabometyx-h-c-004163-ii-0005-epar-assessment-report-variation_en.pdf